FindTrial
Sign In

Meningococcal vaccine GSK134612

BIOLOGICAL13 trials

Sponsors

GlaxoSmithKline, Pfizer

Conditions

Infections, Meningococcal

Phase 2

Immunogenicity and Safety of Meningococcal Vaccine GSK134612 Given as 1 or 2 Doses to Healthy 9-12 Months Old Toddlers.
CompletedNCT00471081
GlaxoSmithKlineInfections, Meningococcal
Start: 2007-07-05End: 2008-11-26Updated: 2019-06-25
The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Toddlers
CompletedNCT00718666
GlaxoSmithKlineInfections, Meningococcal
Start: 2008-10-20End: 2014-03-28Updated: 2019-06-26

Phase 3

Lot Consistency, Immuno, Safety of Meningococcal Vaccine GSK134612 Given With Fluarix™ to 18-55 Year-Old Adults
CompletedNCT00453986
GlaxoSmithKlineInfections, Meningococcal
Start: 2007-04-09End: 2008-05-21Updated: 2018-09-25
Non-Inferiority of Meningococcal Vaccine GSK134612 Versus Mencevax™ in 11-17 Year-Old Subjects
CompletedNCT00464815
GlaxoSmithKlineInfections, Meningococcal
Start: 2007-05-02End: 2008-09-10Updated: 2018-06-08
Co-Administration of Meningococcal Vaccine GSK134612 With Infanrix Hexa™ Versus Individual Administration of Each Vaccine
CompletedNCT00508261
GlaxoSmithKlineInfections, Meningococcal
Start: 2007-08-01End: 2008-10-27Updated: 2019-01-24
Co-administration of Meningococcal Vaccine GSK134612 and Pneumococcal Vaccine GSK1024850A vs Individual Administration
CompletedNCT00758264
GlaxoSmithKlineInfections, Meningococcal
Start: 2008-10-30End: 2009-11-02Updated: 2018-05-09
Study to Evaluate Persistence of Antibodies After Vaccination With Meningococcal Vaccine GSK134612
CompletedNCT00955682
GlaxoSmithKlineInfections, Meningococcal
Start: 2009-08-25End: 2012-09-10Updated: 2021-02-26
Comparison of GlaxoSmithKline (GSK)134612 in Subjects With Increased Risk for Meningococcal Disease Versus Healthy Subjects
CompletedNCT01641042
GlaxoSmithKlineInfections, Meningococcal
Start: 2012-09-10End: 2015-03-03Updated: 2017-10-18
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine With or Without Co-administration of Cervarix and Boostrix in Female Adolescents and Young Adults
CompletedNCT01755689
GlaxoSmithKlineInfections, Meningococcal
Start: 2013-01-11End: 2014-04-29Updated: 2018-07-03
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Conjugate Vaccine (GSK134612) When Co-administered With Boostrix® in Subjects Between 11 and 25 Years of Age
CompletedNCT01767376
GlaxoSmithKlineInfections, Meningococcal
Start: 2013-01-10End: 2014-01-16Updated: 2017-09-06
Study to Evaluate the Long-term Antibody Persistence of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine (GSK134612) Versus Mencevax ACWY in Healthy Adolescents and Adults and Booster Response to MenACWY-TT Vaccine Administered at 10 Years Post-primary Vaccination
CompletedNCT01934140
PfizerInfections, Meningococcal
Start: 2014-04-30End: 2018-08-31Updated: 2019-08-28
Immunogenicity and Safety Study of 1 and 2 Doses of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine MenACWY-TT (GSK134612) in Toddlers, Persistence up to 5 Years After Vaccination and Co-administration With Pfizer's Prevenar 13™Vaccine
CompletedNCT01939158
PfizerInfections, Meningococcal
Start: 2013-10-02End: 2019-12-05Updated: 2021-10-05
The Long-term Antibody Persistence of MenACWY-TT Vaccine (PF-06866681) Versus Meningitec(Registered) or Mencevax(Registered) ACWY in Healthy Adolescents and Adults and a Booster Dose of MenACWY-TT Administered 10 Years Post Primary Vaccination
CompletedNCT01962207
PfizerInfections, Meningococcal
Start: 2013-10-31End: 2018-06-30Updated: 2019-06-07

Related Papers

A phase 3, randomized, controlled, open-label study to evaluate the persistence up to 5 years of 1 or 2 doses of meningococcal conjugate vaccine MenACWY-TT given with or without 13-valent pneumococcal conjugate vaccine in 12-14-month-old children.
2023-01-063 citations
A phase 2b/3b MenACWY-TT study of long-term antibody persistence after primary vaccination and immunogenicity and safety of a booster dose in individuals aged 11 through 55 years
BMC Infectious Diseases2020-06-1811 citations
Ten-Year Antibody Persistence and Booster Response to MenACWY-TT Vaccine After Primary Vaccination at 1-10 Years of Age
Human Vaccines & Immunotherapeutics2020-06-0215 citations
1478. Efficacy and Safety of a Booster Dose of the MenACWY-TT Vaccine Administered 10 Years After Primary Vaccination with MenACWY-TT or MenACWY-PS
Open Forum Infectious Diseases2019-10-01
2722 B. Efficacy and Safety of a Booster Dose of the MenACWY-TT Vaccine Administered 10 Years After Primary Vaccination with MenACWY-TT or MenACWY-PS
Open Forum Infectious Diseases2019-10-01
Immunogenicity and safety of the quadrivalent meningococcal vaccine MenACWY-TT co-administered with a combined diphtheria-tetanus-acellular pertussis vaccine versus their separate administration in adolescents and young adults: A phase III, randomized study.
2018-06-288 citations
MenACWY-TT is immunogenic when co-administered with Tdap and AS04-HPV16/18 in girls and young women: Results from a phase III randomized trial
Vaccine2018-05-199 citations
Immunogenicity and safety of the quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in splenectomized or hyposplenic children and adolescents: Results of a phase III, open, non-randomized study.
2018-03-225 citations
Immunogenicity and safety of one or two doses of the quadrivalent meningococcal vaccine MenACWY-TT given alone or with the 13-valent pneumococcal conjugate vaccine in toddlers: A phase III, open-label, randomised study.
2018-03-0213 citations
Antibody persistence up to 5 y after vaccination with a quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine in adolescents
Human Vaccines & Immunotherapeutics2017-02-0224 citations
Five-year Antibody Persistence and Booster Response After 1 or 2 Doses of Meningococcal A, C, W and Y Tetanus Toxoid Conjugate Vaccine in Healthy Children.
2016-06-0111 citations
Persistence of the immune response two years after vaccination with quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in Asian adolescents
Human Vaccines & Immunotherapeutics2016-05-065 citations
Immunogenicity, Safety and Antibody Persistence of a Booster Dose of Quadrivalent Meningococcal ACWY-tetanus Toxoid Conjugate Vaccine Compared with Monovalent Meningococcal Serogroup C Vaccine Administered Four Years After Primary Vaccination Using the Same Vaccines.
2015-12-0120 citations
Antibody persistence up to 5 years after vaccination of toddlers and children between 12 months and 10 years of age with a quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine
Human Vaccines & Immunotherapeutics2015-11-1729 citations
Immunogenicity and safety of a booster dose of the 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine coadministered with the tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in toddlers: a randomized trial.
2013-01-0116 citations
The immunogenicity and safety of an investigational meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate vaccine (ACWY-TT) compared with a licensed meningococcal tetravalent polysaccharide vaccine: a randomized, controlled non-inferiority study.
2012-04-0923 citations
The investigational meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate vaccine (ACWY-TT) and the seasonal influenza virus vaccine are immunogenic and well-tolerated when co-administered in adults.
2012-04-0916 citations